{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:48:22Z","timestamp":1787021302721,"version":"build-2736575974"},"reference-count":29,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Union - NextGenerationEU","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}]},{"name":"European Union - NextGenerationEU","award":["I53C22001440006"],"award-info":[{"award-number":["I53C22001440006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anaplastic thyroid cancer (ATC), pure or mixed, is the most aggressive form of thyroid cancer that leads to rapid death if left untreated. BRAF V600E is the most frequent pathogenic variant of ATC. Dabrafenib and Trametinib (D+T) have shown promising efficacy and are approved as first-line therapy for unresectable BRAF-mutant ATC. We report a case of fatal aero-digestive perforation in a patient treated with D+T. A 56-year-old man presented with an enlarging cervical mass and airway compromise. BRAF V600E-mutant high-grade papillary thyroid carcinoma with an anaplastic component and tracheal invasion was diagnosed. Due to unresectable disease, D+T therapy was initiated. The patient showed rapid clinical improvement and tumor shrinkage. However, he developed acute respiratory failure after a few days. Imaging revealed a large tracheal perforation and subcutaneous emphysema. D+T was discontinued, but the patient died soon from massive hemorrhage. Aero-digestive perforations have been described with antiangiogenic multikinase inhibitors, but never reported with D+T. In this case, rapid tumor shrinkage likely caused weakening and rupture of the trachea, leading to a fatal perforation. This highlights a potential risk of D+T in cases with extensive invasion of vital structures.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag027","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:37:24Z","timestamp":1769258244000},"source":"Crossref","is-referenced-by-count":1,"title":["Fatal tracheal perforation following Dabrafenib-Trametinib therapy in\n                    <i>BRAF<\/i>\n                    V600E-mutant mixed anaplastic thyroid cancer"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-4717","authenticated-orcid":false,"given":"Antonio","family":"Matrone","sequence":"first","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Scordo","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Minaldi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liborio","family":"Torregrossa","sequence":"additional","affiliation":[{"name":"Pathology Unit 3, Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa , Pisa 56126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Materazzi","sequence":"additional","affiliation":[{"name":"Endocrine Surgery Unit, Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa , Pisa 56126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"13","key":"2026022301040882700_luag027-B1","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.3390\/cancers13133200","article-title":"Poorly differentiated and anaplastic thyroid cancer: insights into genomics, microenvironment and new drugs","volume":"13","author":"Prete","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026022301040882700_luag027-B2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2026022301040882700_luag027-B3","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"issue":"10","key":"2026022301040882700_luag027-B4","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"issue":"6","key":"2026022301040882700_luag027-B5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00268-012-1437-z","article-title":"Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients","volume":"36","author":"Sugitani","year":"2012","journal-title":"World J Surg"},{"issue":"1","key":"2026022301040882700_luag027-B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1245\/s10434-022-12553-6","article-title":"Coexisting papillary and anaplastic thyroid cancer: elucidating the Spectrum of aggressive behavior","volume":"30","author":"Greenberg","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"2026022301040882700_luag027-B7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1089\/thy.2023.0164","article-title":"Factors associated with survival in anaplastic thyroid carcinoma: a multicenter study from the ENDOCAN-TUTHYREF network","volume":"33","author":"Jannin","year":"2023","journal-title":"Thyroid"},{"issue":"12","key":"2026022301040882700_luag027-B8","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1210\/jc.2017-01180","article-title":"Survival in response to multimodal therapy in anaplastic thyroid cancer","volume":"102","author":"Prasongsook","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026022301040882700_luag027-B9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1089\/thy.2025.0044","article-title":"Reimagining the therapeutic approach for anaplastic thyroid cancer: the roadmap to a cure","volume":"35","author":"Cabanillas","year":"2025","journal-title":"Thyroid"},{"issue":"3","key":"2026022301040882700_luag027-B10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"issue":"3","key":"2026022301040882700_luag027-B11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"issue":"3","key":"2026022301040882700_luag027-B12","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"2026022301040882700_luag027-B13","first-page":"9174","article-title":"Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: a single institute experience","volume":"15","author":"Romei","year":"2018","journal-title":"Oncol Lett"},{"issue":"3","key":"2026022301040882700_luag027-B14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.beem.2017.06.001","article-title":"Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: from the clinical trials to the real life","volume":"31","author":"Matrone","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2026022301040882700_luag027-B15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"2026022301040882700_luag027-B16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"2026022301040882700_luag027-B17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/jamaoncol.2024.2133","article-title":"Initial management of BRAF V600E-variant anaplastic thyroid cancer: the FAST multidisciplinary group consensus statement","volume":"10","author":"Hamidi","year":"2024","journal-title":"JAMA oncology"},{"key":"2026022301040882700_luag027-B18","author":"CTEP"},{"issue":"5","key":"2026022301040882700_luag027-B19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000514182","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio","year":"2021","journal-title":"Eur Thyroid J"},{"key":"2026022301040882700_luag027-B20","doi-asserted-by":"crossref","first-page":"854755","DOI":"10.3389\/fonc.2022.854755","article-title":"Core needle biopsy can early and precisely identify large thyroid masses","volume":"12","author":"Matrone","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"2026022301040882700_luag027-B21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1385\/EP:15:4:319","article-title":"Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas","volume":"15","author":"Nikiforov","year":"2004","journal-title":"Endocr Pathol"},{"issue":"11","key":"2026022301040882700_luag027-B22","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026022301040882700_luag027-B23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"29","key":"2026022301040882700_luag027-B24","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026022301040882700_luag027-B25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1089\/thy.2012.0598","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins","year":"2014","journal-title":"Thyroid"},{"key":"2026022301040882700_luag027-B26","doi-asserted-by":"crossref","first-page":"1002291","DOI":"10.37349\/etat.2025.1002291","article-title":"Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer","volume":"6","author":"Valerio","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"issue":"8","key":"2026022301040882700_luag027-B27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"2026022301040882700_luag027-B28","doi-asserted-by":"crossref","first-page":"106625","DOI":"10.1016\/j.oraloncology.2023.106625","article-title":"Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer","volume":"147","author":"Farlow","year":"2023","journal-title":"Oral Oncol"},{"issue":"3","key":"2026022301040882700_luag027-B29","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00405-023-07827-y","article-title":"Mutation-based, short-term \u201cneoadjuvant\u201d treatment allows resectability in stage IVB and C anaplastic thyroid cancer","volume":"280","author":"Maurer","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/3\/luag027\/67067499\/luag027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/3\/luag027\/67067499\/luag027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:04:16Z","timestamp":1771826656000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag027\/8494623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag027","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,23]]},"article-number":"luag027"}}